Biotechnology

A new class of ultra-flexible graphene brain implants has safely decoded neural signals in a first-in-human study, heralding a new era for surgery.

With Cigna's backing, Accord's IMULDOSA is set to challenge a blockbuster drug, promising significant savings for patients and the healthcare system.

NAMSA appoints commercial leader Scott Day as VP, signaling a strategic push to expand its end-to-end clinical and consulting services amid industry growth.

New preclinical data reveals a T cell engager targeting multiple cancer markers at once, a novel strategy to overcome immunotherapy's limits in solid tumors.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

Biogen consolidates worldwide rights for its promising immunology drug felzartamab, acquiring China rights from TJ Biopharma in a strategic $850M deal.

A Shanghai-based firm's new approach could create cancer-fighting cells inside the body, slashing costs and wait times for CAR-T therapy.

A Swiss-Indian partnership aims to halt diseases like Alzheimer's and ALS by repairing damaged cell membranes, a groundbreaking approach to a global crisis.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

A new gene therapy that reprograms cancer cells into immune activators shows major promise, blending personalized treatment with off-the-shelf convenience.

A landmark real-world study from England shows maternal RSV vaccination slashes infant hospitalizations, validating a powerful new shield for newborns.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

New data on ATX-295 reveals a potent attack on unstable tumors, guided by an AI biomarker that could change how we select patients for treatment.

Nested Therapeutics' NST-628 reports a 38% response rate in advanced melanoma, offering new hope with a novel, brain-penetrating cancer-fighting agent.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

A surprise $5 million pledge for glaucoma research highlights a gala honoring philanthropist Daria Barry, patient advocate Hillary Golden, and music icon Nile Rodgers.

Vaxart's new $25M financing deal provides a crucial cash runway, but is it a savvy strategic move or a necessary step to stay in the race?

With global regulatory approvals secured, Gilead extends its tender offer for Arcellx, moving closer to acquiring a potential best-in-class CAR T therapy.

A new report reveals the Nordic life science sector isn't lacking female talent; it's failing to convert it into leadership, threatening innovation.

Early Phase 2 data shows invikafusp alfa plus TRODELVY® yields complete responses in heavily pretreated breast cancer, offering a potential new lifeline.